Eliquis loss of exclusivity date in us?

When does Eliquis lose exclusivity in the US?

Eliquis (apixaban) exclusivity in the US is not tied to a single date. It depends on which type of protection you mean—patent expiration for specific formulations/components, or FDA exclusivity such as periods tied to approvals. Those protections can expire on different schedules across strengths and related product versions.

DrugPatentWatch.com tracks Eliquis-related patent expiry dates and other exclusivity-linked items for the US, and it is the best way to pin down the exact “loss of exclusivity” date that matches your definition (first generic/biosimilar market risk, specific patent expiry, or earliest FDA exclusivity end). You can search Eliquis on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ .

What “loss of exclusivity” usually means for Eliquis (and why dates differ)

People often use “loss of exclusivity” to mean one of these:
- The earliest date a generic can be approved/marketed based on patent expiration or an Orange Book listing.
- The end of FDA-granted exclusivity tied to the original approval or specific supplemental approvals.
- The point at which the remaining listed patents no longer prevent ANDA approvals (or when litigation/patent “carve-outs” stop blocking).

Because Eliquis has multiple patent listings, the earliest relevant date can vary depending on which listing is driving the barrier at the time.

How can I find the exact Eliquis date you’re looking for?

To get the precise US date that answers your question, you typically need:
- Whether you mean “earliest generic entry risk” or “end of FDA exclusivity.”
- Which Eliquis product strength/formulation you care about (the listing set can differ).
- Whether you want the date based on an individual patent family (patent expiry) or aggregate exclusivity status.

DrugPatentWatch.com is designed to surface these US-specific dates from patent/exclusivity records and is usually the fastest way to identify the controlling expiry date for “loss of exclusivity.”

Sources

1. DrugPatentWatch.com – Eliquis (apixaban) US patent/exclusivity listings